AAPL336.13-0.87 (-0.26%) ▼|ABBV263.96-0.06 (-0.02%) ▼|ABT102.61+0.38 (+0.37%) ▲|ACN181.29-9.00 (-4.73%) ▼|ADBE248.92-3.75 (-1.48%) ▼|AMAT444.57+27.17 (+6.51%) ▲|AMD559.82+14.73 (+2.70%) ▲|AMGN385.65+5.87 (+1.55%) ▲|AMT173.98-1.60 (-0.91%) ▼|AMZN253.71+2.52 (+1.00%) ▲|AVGO357.61+10.31 (+2.97%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA198.20+1.20 (+0.61%) ▲|BAC57.73-0.45 (-0.77%) ▼|BKNG167.90-2.62 (-1.54%) ▼|BLK1,069.78+15.82 (+1.50%) ▲|BMY63.06+0.22 (+0.35%) ▲|BNY153.79+0.77 (+0.50%) ▲|BRK-B509.77+0.57 (+0.11%) ▲|C131.77-0.93 (-0.70%) ▼|CAT808.99+10.42 (+1.30%) ▲|CL87.47-0.26 (-0.30%) ▼|CMCSA22.74-0.17 (-0.74%) ▼|COF202.43+0.39 (+0.19%) ▲|COP131.83-1.36 (-1.02%) ▼|COST895.31+1.38 (+0.15%) ▲|CRM237.92-4.93 (-2.03%) ▼|CSCO109.51-0.73 (-0.66%) ▼|CVS88.84-1.43 (-1.58%) ▼|CVX209.51-2.06 (-0.97%) ▼|DE683.99-1.64 (-0.24%) ▼|DHR211.81-0.69 (-0.32%) ▼|DIS102.67-2.68 (-2.54%) ▼|DUK117.53-1.01 (-0.85%) ▼|EMR149.92+2.52 (+1.71%) ▲|FDX303.65-2.23 (-0.73%) ▼|GD353.05-2.90 (-0.81%) ▼|GE314.27+0.80 (+0.26%) ▲|GEV940.33+15.40 (+1.67%) ▲|GILD150.11-0.78 (-0.52%) ▼|GM82.20-4.42 (-5.10%) ▼|GOOG344.41+0.73 (+0.21%) ▲|GOOGL349.54+2.21 (+0.64%) ▲|GS942.00-9.47 (-1.00%) ▼|HD299.98-2.53 (-0.84%) ▼|HON206.46-0.03 (-0.01%) ▼|IBM229.55-8.20 (-3.45%) ▼|INTC108.60-0.20 (-0.18%) ▼|INTU303.19-9.94 (-3.17%) ▼|ISRG393.33+9.79 (+2.55%) ▲|JNJ269.99-0.23 (-0.09%) ▼|JPM349.67+0.36 (+0.10%) ▲|KO88.25+0.19 (+0.22%) ▲|LIN460.40+1.92 (+0.42%) ▲|LLY1,152.93+0.49 (+0.04%) ▲|LMT533.38-4.71 (-0.88%) ▼|LOW192.49-1.70 (-0.88%) ▼|LRCX288.11+18.80 (+6.98%) ▲|MA565.24-0.49 (-0.09%) ▼|MCD248.24-0.24 (-0.10%) ▼|MDLZ60.85-1.19 (-1.92%) ▼|MDT92.13-0.64 (-0.69%) ▼|META665.75-16.56 (-2.43%) ▼|MMM165.89+1.18 (+0.72%) ▲|MO69.52-0.18 (-0.26%) ▼|MRK146.87-0.28 (-0.19%) ▼|MS202.58-0.94 (-0.46%) ▼|MSFT493.78-3.97 (-0.80%) ▼|MU1,015.80+38.30 (+3.92%) ▲|NEE80.47-0.81 (-1.00%) ▼|NFLX71.79-3.52 (-4.67%) ▼|NKE35.51-0.85 (-2.34%) ▼|NOW135.47-3.00 (-2.17%) ▼|NVDA222.27+2.93 (+1.34%) ▲|ORCL147.61-2.98 (-1.98%) ▼|PEP129.75-3.91 (-2.93%) ▼|PFE27.66+0.02 (+0.07%) ▲|PG146.39-1.16 (-0.79%) ▼|PLTR177.64+1.40 (+0.79%) ▲|PM188.62-1.86 (-0.98%) ▼|QCOM177.72-10.99 (-5.82%) ▼|RTX194.00+0.46 (+0.24%) ▲|SBUX95.83-0.84 (-0.87%) ▼|SCHW105.25+0.62 (+0.59%) ▲|SO85.52-1.24 (-1.43%) ▼|SPG205.32+0.85 (+0.42%) ▲|T25.40+0.01 (+0.04%) ▲|TMO651.45-6.87 (-1.04%) ▼|TMUS168.18+1.73 (+1.04%) ▲|TSLA364.27-1.93 (-0.53%) ▼|TXN266.64+8.50 (+3.29%) ▲|UBER70.50-0.37 (-0.52%) ▼|UNH376.90+1.69 (+0.45%) ▲|UNP279.37-3.11 (-1.10%) ▼|UPS99.06-1.11 (-1.11%) ▼|USB60.06-0.19 (-0.32%) ▼|V368.29-1.64 (-0.44%) ▼|VZ48.09-0.24 (-0.50%) ▼|WFC86.12-0.77 (-0.89%) ▼|WMT106.73-0.06 (-0.06%) ▼|XOM163.54+0.27 (+0.17%) ▲|AAPL336.13-0.87 (-0.26%) ▼|ABBV263.96-0.06 (-0.02%) ▼|ABT102.61+0.38 (+0.37%) ▲|ACN181.29-9.00 (-4.73%) ▼|ADBE248.92-3.75 (-1.48%) ▼|AMAT444.57+27.17 (+6.51%) ▲|AMD559.82+14.73 (+2.70%) ▲|AMGN385.65+5.87 (+1.55%) ▲|AMT173.98-1.60 (-0.91%) ▼|AMZN253.71+2.52 (+1.00%) ▲|AVGO357.61+10.31 (+2.97%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA198.20+1.20 (+0.61%) ▲|BAC57.73-0.45 (-0.77%) ▼|BKNG167.90-2.62 (-1.54%) ▼|BLK1,069.78+15.82 (+1.50%) ▲|BMY63.06+0.22 (+0.35%) ▲|BNY153.79+0.77 (+0.50%) ▲|BRK-B509.77+0.57 (+0.11%) ▲|C131.77-0.93 (-0.70%) ▼|CAT808.99+10.42 (+1.30%) ▲|CL87.47-0.26 (-0.30%) ▼|CMCSA22.74-0.17 (-0.74%) ▼|COF202.43+0.39 (+0.19%) ▲|COP131.83-1.36 (-1.02%) ▼|COST895.31+1.38 (+0.15%) ▲|CRM237.92-4.93 (-2.03%) ▼|CSCO109.51-0.73 (-0.66%) ▼|CVS88.84-1.43 (-1.58%) ▼|CVX209.51-2.06 (-0.97%) ▼|DE683.99-1.64 (-0.24%) ▼|DHR211.81-0.69 (-0.32%) ▼|DIS102.67-2.68 (-2.54%) ▼|DUK117.53-1.01 (-0.85%) ▼|EMR149.92+2.52 (+1.71%) ▲|FDX303.65-2.23 (-0.73%) ▼|GD353.05-2.90 (-0.81%) ▼|GE314.27+0.80 (+0.26%) ▲|GEV940.33+15.40 (+1.67%) ▲|GILD150.11-0.78 (-0.52%) ▼|GM82.20-4.42 (-5.10%) ▼|GOOG344.41+0.73 (+0.21%) ▲|GOOGL349.54+2.21 (+0.64%) ▲|GS942.00-9.47 (-1.00%) ▼|HD299.98-2.53 (-0.84%) ▼|HON206.46-0.03 (-0.01%) ▼|IBM229.55-8.20 (-3.45%) ▼|INTC108.60-0.20 (-0.18%) ▼|INTU303.19-9.94 (-3.17%) ▼|ISRG393.33+9.79 (+2.55%) ▲|JNJ269.99-0.23 (-0.09%) ▼|JPM349.67+0.36 (+0.10%) ▲|KO88.25+0.19 (+0.22%) ▲|LIN460.40+1.92 (+0.42%) ▲|LLY1,152.93+0.49 (+0.04%) ▲|LMT533.38-4.71 (-0.88%) ▼|LOW192.49-1.70 (-0.88%) ▼|LRCX288.11+18.80 (+6.98%) ▲|MA565.24-0.49 (-0.09%) ▼|MCD248.24-0.24 (-0.10%) ▼|MDLZ60.85-1.19 (-1.92%) ▼|MDT92.13-0.64 (-0.69%) ▼|META665.75-16.56 (-2.43%) ▼|MMM165.89+1.18 (+0.72%) ▲|MO69.52-0.18 (-0.26%) ▼|MRK146.87-0.28 (-0.19%) ▼|MS202.58-0.94 (-0.46%) ▼|MSFT493.78-3.97 (-0.80%) ▼|MU1,015.80+38.30 (+3.92%) ▲|NEE80.47-0.81 (-1.00%) ▼|NFLX71.79-3.52 (-4.67%) ▼|NKE35.51-0.85 (-2.34%) ▼|NOW135.47-3.00 (-2.17%) ▼|NVDA222.27+2.93 (+1.34%) ▲|ORCL147.61-2.98 (-1.98%) ▼|PEP129.75-3.91 (-2.93%) ▼|PFE27.66+0.02 (+0.07%) ▲|PG146.39-1.16 (-0.79%) ▼|PLTR177.64+1.40 (+0.79%) ▲|PM188.62-1.86 (-0.98%) ▼|QCOM177.72-10.99 (-5.82%) ▼|RTX194.00+0.46 (+0.24%) ▲|SBUX95.83-0.84 (-0.87%) ▼|SCHW105.25+0.62 (+0.59%) ▲|SO85.52-1.24 (-1.43%) ▼|SPG205.32+0.85 (+0.42%) ▲|T25.40+0.01 (+0.04%) ▲|TMO651.45-6.87 (-1.04%) ▼|TMUS168.18+1.73 (+1.04%) ▲|TSLA364.27-1.93 (-0.53%) ▼|TXN266.64+8.50 (+3.29%) ▲|UBER70.50-0.37 (-0.52%) ▼|UNH376.90+1.69 (+0.45%) ▲|UNP279.37-3.11 (-1.10%) ▼|UPS99.06-1.11 (-1.11%) ▼|USB60.06-0.19 (-0.32%) ▼|V368.29-1.64 (-0.44%) ▼|VZ48.09-0.24 (-0.50%) ▼|WFC86.12-0.77 (-0.89%) ▼|WMT106.73-0.06 (-0.06%) ▼|XOM163.54+0.27 (+0.17%) ▲|
19.7 C
New York
Sunday, September 20, 2026

Tag: 6

newssourceFORcompanyinformationcontent1releasesmarket

Time Temperature Indicator Market to Reach $1.57 Billion by 2035, Growing at a CAGR of 6.2% from 2025–Exclusive Report by Meticulous Research®

Market Growth Driven by Cold Chain Expansion, IoT Integration, Regulatory Compliance Requirements, and Focus on Food Safety REDDING, Calif., June 20, 2025 /PRNewswire/ -- According to...

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.

1000 MIGLIA 2025, today the leg that will unite the Adriatic and Tyrrhenian seas

Departing early in the morning from Cervia, the crews will stop in Pontedera for lunch. Following this, entry into the Naval Academy in Livorno will complete the crossing of Italy from east to west 
Departing early in the morning from Cervia, the crews will stop in Pontedera for lunch. Following this, entry into the Naval Academy in Livorno will complete the crossing of Italy from east to west

castLabs delivers new React Native player SDK to expand 3SS’ 3Ready solution for Proximus

BERLIN, June 20, 2025 /PRNewswire/ -- castLabs, a global pioneer in premium digital video technology, and 3 Screen Solutions (3SS), leading provider of software...

GirlStyle Unveils Inaugural “GirlStyle NextGen Glowing Awards 2025,” Illuminating the Future of Beauty

HONG KONG, June 20, 2025 /PRNewswire/ -- The beauty industry marks a significant milestone! GirlStyle, a leading female lifestyle information platform under PressLogic, proudly...

BW Energy: Update on Fixed Income Investor Meetings  

Update on Fixed Income Investor Meetings  

TECNO POVA 7 Series Launches: Boasting Refreshing Trendy Design, AI-Driven Gaming Power and Numerous Surprising Features

HONG KONG, June 20, 2025 /PRNewswire/ -- TECNO, an AI-driven innovative technology brand, unveils the POVA 7 Series today with the most significant performance...

New Global Aesthetics Report: A Shift Towards Facial Surgery Globally as Eyelid Ranks Top Procedure

Aesthetic Procedures Close to 38 Million in 2024. MOUNT ROYAL, N.J., June 20, 2025 /CNW/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the...

EMA Confluence Validates Trend Continuation Setup

OverviewThe Multiple EMA Trend Confirmation Trading System is rooted in technical analysis, leveraging Exponential Moving Averages (EMAs) and multi-timeframe charts to identify trend direction...

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Analyzing Annuity Costs: A Detailed Breakdown for Strategic Financial Planning

Annuities, while potentially beneficial under certain circumstances, require careful scrutiny due to their associated costs. The primary concern is the substantial fees that can...

Fed Maintains Interest Rates—Evaluate Implications for Credit Cards, Auto Loans, Mortgages

The Federal Reserve's decision to maintain the current interest rate reflects a strategic pause amid an evolving economic landscape. Given President Trump's calls for...

Cochlear celebrates 30 Years in China and the launch of the world’s first and only smart hearing implant system

The new Cochlear™ Nucleus® Nexa™ System is the first and only hearing implant featuring internal memory and upgradeable firmware.1+This year marks the 30-year anniversary since...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags6

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers